BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Recordati S.p.A 

Via M. Civitali, 1

Milan    20148  Italy
Phone: 39-02-487871 Fax: 39-02-40073747


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Pharmaceutical


Collaborations

Forest Laboratories, Inc.  Licensing agreement for the development of lercanidipine, a long-acting dihydropyridine calcium channel blocker for the treatment of hypertension.

Digital Gene Technologies  Atherosclerosis





 Company News
Recordati S.p.A Finalizes The Second Tranche Of Its Acquisition Of Opalia Pharma In Tunisia 5/27/2014 9:37:15 AM
Prasco Laboratories Announces Authorized Generic Agreement With Recordati S.p.A 5/22/2014 9:35:51 AM
Recordati S.p.A: Sales Growth And Significant Margin Improvement In The First Quarter 2014 5/6/2014 9:13:51 AM
Recordati S.p.A: Shareholders Approve The 2013 Accounts. Dividend EU 0.33 Per Share 4/17/2014 9:43:43 AM
Gebro Pharma Signs A Licensing Agreement With Recordati S.p.A For The Commercialization Of Kentera® In Spain 2/27/2014 8:48:10 AM
Recordati S.p.A : Preliminary 2013 Results Show Significant Growth. Sales +13.7%, Ebit +17.0%, Net Income +12.8%. 2/11/2014 9:21:02 AM
Apricus Biosciences (APRI), Recordati S.p.A Forge Erectile Dysfunction Pact Worth $47 Million 2/10/2014 7:13:04 AM
Recordati S.p.A Board Of Directors Approves 2014 Objectives 1/16/2014 9:06:08 AM
Recordati S.p.A Buys Tunisia's Opalia Pharma for 37 Million Euros 7/25/2013 6:35:59 AM
Recordati S.p.A: Significant Sales and Earnings Growth in the First Quarter 2013 5/9/2013 11:05:51 AM
12345678910...